Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
AMLX Amylyx Pharmaceuticals	$5.52	$4.78	$1.58 ▼ $7.27	$492.06M	-0.59	1.20 million shs	890,299 shs
CABA Cabaletta Bio	$1.99 +10.6%	$1.55	$0.99 ▼ $13.50	$100.98M	2.81	1.65 million shs	4.56 million shs
DNA Ginkgo Bioworks	$8.94 -3.8%	$7.61	$5.00 ▼ $18.80	$523.28M	1.25	1.46 million shs	953,127 shs
ORKA Oruka Therapeutics	$12.56 -2.4%	$10.28	$5.49 ▼ $31.13	$470.26M	-0.38	221,429 shs	131,591 shs

20 Stocks to Sell Now

Today, we are inviting you to take a free peek at our proprietary, exclusive, and up-to-the-minute list of 20 stocks that Wall Street's top analysts hate.

Many of these appear to have good fundamentals and might seem like okay investments, but something is wrong. Analysts smell something seriously rotten about these companies. These are true "Strong Sell" stocks.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
AMLX Amylyx Pharmaceuticals	0.00%	+3.56%	+26.90%	+52.07%	+222.81%
CABA Cabaletta Bio	+10.56%	-19.76%	+53.08%	+9.34%	-83.63%
DNA Ginkgo Bioworks	-3.57%	+18.08%	+14.75%	+27.79%	-57.72%
ORKA Oruka Therapeutics	-2.41%	-0.16%	+29.35%	+13.26%	+1,255,999,900.00%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
AMLX Amylyx Pharmaceuticals	4.1343 of 5 stars	4.6	3.0	2.0	4.2	1.3
CABA Cabaletta Bio	2.8578 of 5 stars	4.5	1.0	3.1	0.8	0.6
DNA Ginkgo Bioworks	0.5956 of 5 stars	0.8	1.0	1.6	2.5	1.3
ORKA Oruka Therapeutics	3.0543 of 5 stars	3.6	0.0	3.8	2.5	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
AMLX Amylyx Pharmaceuticals	3.11	Buy	$9.83	78.14% Upside
CABA Cabaletta Bio	3.00	Buy	$20.33	921.78% Upside
DNA Ginkgo Bioworks	1.67	Reduce	$5.77	-35.49% Downside
ORKA Oruka Therapeutics	3.20	Buy	$40.38	221.46% Upside

Current Analyst Ratings Breakdown

Latest CABA, AMLX, ORKA, and DNA Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
6/11/2025	CABA Cabaletta Bio	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$25.00
5/30/2025	AMLX Amylyx Pharmaceuticals	TD Cowen Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy
5/22/2025	ORKA Oruka Therapeutics	BTIG Research Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy
5/22/2025	ORKA Oruka Therapeutics	BTIG Research Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy	$44.00
5/16/2025	CABA Cabaletta Bio	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$17.00 ➝ $13.00
5/15/2025	CABA Cabaletta Bio	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$23.00 ➝ $25.00
5/15/2025	ORKA Oruka Therapeutics	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform ➝ Outperform	$40.00 ➝ $40.00
5/14/2025	AMLX Amylyx Pharmaceuticals	Mizuho Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Outperform ➝ Outperform	$7.00 ➝ $8.00
5/9/2025	AMLX Amylyx Pharmaceuticals	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$12.00 ➝ $16.00
5/7/2025	AMLX Amylyx Pharmaceuticals	Leerink Partners Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Market Perform ➝ Outperform	$4.00 ➝ $10.00
5/6/2025	AMLX Amylyx Pharmaceuticals	Leerink Partnrs Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Hold ➝ Strong-Buy

(Data available from 6/14/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
AMLX Amylyx Pharmaceuticals	-$1.27M	-386.84	$1.00 per share	5.51	$6.42 per share	0.86
CABA Cabaletta Bio	N/A	N/A	N/A	N/A	$5.51 per share	N/A
DNA Ginkgo Bioworks	$237.42M	2.20	N/A	N/A	$21.93 per share	0.41
ORKA Oruka Therapeutics	N/A	N/A	N/A	N/A	N/A	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
AMLX Amylyx Pharmaceuticals	$49.27M	-$3.11	N/A	N/A	N/A	N/A	-36.97%	-29.61%	8/6/2025 (Estimated)
CABA Cabaletta Bio	-$67.68M	-$2.54	N/A	N/A	N/A	N/A	-50.10%	-45.49%	8/6/2025 (Estimated)
DNA Ginkgo Bioworks	-$892.87M	-$9.16	N/A	N/A	N/A	-298.78%	-58.54%	-34.24%	8/14/2025 (Estimated)
ORKA Oruka Therapeutics	-$5.34M	-$4.51	N/A	N/A	N/A	N/A	-24.96%	-21.22%	7/30/2025 (Estimated)

Latest CABA, AMLX, ORKA, and DNA Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/21/2025	Q1 2025	CABA Cabaletta Bio	-$0.67	-$0.71	-$0.04	-$0.71	N/A	N/A
5/14/2025	Q1 2025	ORKA Oruka Therapeutics	-$0.57	-$0.40	+$0.17	-$0.40	N/A	N/A
5/8/2025	Q1 2025	AMLX Amylyx Pharmaceuticals	-$0.45	-$0.42	+$0.03	-$0.42	N/A	N/A
5/6/2025	Q1 2025	DNA Ginkgo Bioworks	-$1.23	-$1.58	-$0.35	-$1.68	$38.70 million	$48.32 million
3/31/2025	Q4 2024	CABA Cabaletta Bio	-$0.65	-$0.65	N/A	-$0.65	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
AMLX Amylyx Pharmaceuticals	$1.02	18.41%	N/A	N/A	N/A
CABA Cabaletta Bio	N/A	N/A	N/A	N/A	N/A
DNA Ginkgo Bioworks	N/A	N/A	N/A	N/A	N/A
ORKA Oruka Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
AMLX Amylyx Pharmaceuticals	N/A	4.55	4.55
CABA Cabaletta Bio	N/A	8.11	8.11
DNA Ginkgo Bioworks	N/A	5.79	5.79
ORKA Oruka Therapeutics	N/A	22.89	22.89

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
AMLX Amylyx Pharmaceuticals	95.84%
CABA Cabaletta Bio	N/A
DNA Ginkgo Bioworks	78.63%
ORKA Oruka Therapeutics	56.44%

Insider Ownership

Company	Insider Ownership
AMLX Amylyx Pharmaceuticals	11.70%
CABA Cabaletta Bio	11.25%
DNA Ginkgo Bioworks	9.72%
ORKA Oruka Therapeutics	24.69%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
AMLX Amylyx Pharmaceuticals	200	89.14 million	60.53 million	Optionable
CABA Cabaletta Bio	50	50.74 million	44.05 million	Optionable
DNA Ginkgo Bioworks	640	58.53 million	51.89 million	Optionable
ORKA Oruka Therapeutics	N/A	37.44 million	27.07 million	N/A

CABA, AMLX, ORKA, and DNA Headlines

Recent News About These Companies

Wall Street Zen Downgrades Oruka Therapeutics (NASDAQ:ORKA) to Sell

June 14 at 1:41 AM | marketbeat.com

Millennium Management LLC Makes New Investment in Oruka Therapeutics, Inc. (NASDAQ:ORKA)

June 8, 2025 | marketbeat.com

Toronto Dominion Bank Takes Position in Oruka Therapeutics, Inc. (NASDAQ:ORKA)

June 1, 2025 | marketbeat.com

ORKA Oruka Therapeutics, Inc.

May 30, 2025 | seekingalpha.com

Q2 EPS Estimate for Oruka Therapeutics Boosted by Analyst

May 30, 2025 | marketbeat.com

Northern Trust Corp Acquires Shares of 64,044 Oruka Therapeutics, Inc. (NASDAQ:ORKA)

May 30, 2025 | marketbeat.com

Jefferies Financial Group Inc. Makes New $6.79 Million Investment in Oruka Therapeutics, Inc. (NASDAQ:ORKA)

May 28, 2025 | marketbeat.com

H.C. Wainwright Maintains Buy Rating on Oruka (ORKA) After the Early Start of OKRA-002 Trial

May 27, 2025 | insidermonkey.com

Oruka Therapeutics, Inc. (NASDAQ:ORKA) Given Consensus Recommendation of "Buy" by Analysts

May 27, 2025 | marketbeat.com

58,332 Shares in Oruka Therapeutics, Inc. (NASDAQ:ORKA) Purchased by Toronto Dominion Bank

May 26, 2025 | marketbeat.com

Oruka Therapeutics (NASDAQ:ORKA) Raised to Hold at StockNews.com

May 24, 2025 | marketbeat.com

Oruka Therapeutics (NASDAQ:ORKA) Coverage Initiated by Analysts at BTIG Research

May 24, 2025 | marketbeat.com

Frazier Life Sciences Management L.P. Grows Holdings in Oruka Therapeutics, Inc. (NASDAQ:ORKA)

May 23, 2025 | marketbeat.com

VR Adviser LLC Buys 200,000 Shares of Oruka Therapeutics, Inc. (NASDAQ:ORKA)

May 22, 2025 | marketbeat.com

Point72 Asset Management L.P. Cuts Position in Oruka Therapeutics, Inc. (NASDAQ:ORKA)

May 22, 2025 | marketbeat.com

Oruka Therapeutics begins trial for psoriasis treatment

May 21, 2025 | uk.investing.com

Oruka Therapeutics to Present at the Jefferies Global Healthcare Conference

May 21, 2025 | globenewswire.com

Oruka Therapeutics Announces First Participants Dosed in Phase 1 Trial of ORKA-002, its Novel Half-life Extended Anti-IL-17A/F Antibody

May 20, 2025 | globenewswire.com

Wedbush Forecasts Reduced Earnings for Oruka Therapeutics

May 20, 2025 | marketbeat.com

RTW Investments LP Boosts Stock Position in Oruka Therapeutics, Inc. (NASDAQ:ORKA)

May 18, 2025 | marketbeat.com

Polar Capital Holdings Plc Buys New Stake in Oruka Therapeutics, Inc. (NASDAQ:ORKA)

May 18, 2025 | marketbeat.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

CABA, AMLX, ORKA, and DNA Company Descriptions

Amylyx Pharmaceuticals NASDAQ:AMLX

$5.52 0.00 (0.00%)

Closing price 06/13/2025 04:00 PM Eastern

Extended Trading

$5.51 -0.01 (-0.18%)

As of 06/13/2025 07:15 PM Eastern

Amylyx Pharmaceuticals, Inc., a commercial-stage biotechnology company, engages in the discovery and development of treatment for amyotrophic lateral sclerosis (ALS) and neurodegenerative diseases. The company's products include RELYVRIO, a dual UPR-Bax apoptosis inhibitor composed of sodium phenylbutyrate and taurursodiol for the treatment of ALS in adults in the United States and marketed as ALBRIOZA for the treatment of ALS in Canada. It is also developing AMX0114 for other neurodegenerative diseases. Amylyx Pharmaceuticals, Inc. was founded in 2013 and is headquartered in Cambridge, Massachusetts.

Cabaletta Bio NASDAQ:CABA

$1.99 +0.19 (+10.56%)

Closing price 06/13/2025 04:00 PM Eastern

Extended Trading

$1.96 -0.03 (-1.76%)

As of 06/13/2025 07:50 PM Eastern

Cabaletta Bio, Inc., a clinical-stage biotechnology company, focuses on the discovery and development of engineered T cell therapies for patients with B cell-mediated autoimmune diseases. The company's lead product candidate is CABA-201, a fully human anti-CD19 binder for the treatment of Phase 1/2 clinical trials in dermatomyositis, anti-synthetase syndrome, immune-mediated necrotizing myopathy, lupus nephritis, non-renal systemic lupus erythematosus, systemic sclerosis, and generalized myasthenia gravis. It also develops DSG3-CAART, which is in Phase I/II clinical trial for the treatment of mucosal pemphigus vulgaris; and MuSK-CAART, an investigational cell therapy that is in Phase I/II clinical trial for treating patients with anti- muscle-specific kinase antibody positive myasthenia gravis. It has a collaboration with the University of Pennsylvania and the Children's Hospital of Philadelphia; Nanjing IASO Biotherapeutics Co., Ltd; Oxford Biomedica; and WuXi Advanced Therapies, Inc. The company was formerly known as Tycho Therapeutics, Inc. and changed its name to Cabaletta Bio, Inc. in August 2018. Cabaletta Bio, Inc. was incorporated in 2017 and is headquartered in Philadelphia, Pennsylvania.

Ginkgo Bioworks NYSE:DNA

$8.94 -0.35 (-3.78%)

Closing price 06/13/2025 03:59 PM Eastern

Extended Trading

$9.20 +0.26 (+2.92%)

As of 06/13/2025 07:59 PM Eastern

Ginkgo Bioworks Holdings, Inc., together with its subsidiaries, develops platform for cell programming in the United States. Its platform is used to program cells to enable biological production of products, such as novel therapeutics, food ingredients, and chemicals derived from petroleum. It serves pharma and biotech, agriculture, industrial and environment, food and nutrition, consumer and technology, and government and defense industries. Ginkgo Bioworks Holdings, Inc. was founded in 2008 and is headquartered in Boston, Massachusetts.

Oruka Therapeutics NASDAQ:ORKA

$12.56 -0.31 (-2.41%)

Closing price 06/13/2025 04:00 PM Eastern

Extended Trading

$12.58 +0.02 (+0.16%)

As of 06/13/2025 04:04 PM Eastern

Oruka Therapeutics, Inc. is a biotechnology company, which focuses on developing novel monoclonal antibody therapeutics for PsO and other I&I indications. Its pipeline includes ORKA-001 and ORKA-002. The company is headquartered in Menlo Park, CA.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time